Metastasis Clinical Trial
— OSTRIChOfficial title:
A Randomized, Open Label, Phase IIB Trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated With Docetaxel
Verified date | April 2022 |
Source | The Netherlands Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale: The aim of this study is to identify the optimal second line treatment option for patients with a poor prognosis metastasized Castration Resistant Prostate Cancer (mCRPC) with respect to Clinical Benefit Rate (CBR) rate and quality of life. Objective: The primary endpoint is CBR in mCRPC patients with poor prognostic features and previously treated with docetaxel, randomized between cabazitaxel (Arm A) and novel hormonal agents (abiraterone OR enzalutamide) as second-line therapy (Arm B). Intervention: Patients in Arm A will receive cabazitaxel and prednisone and patients in Arm B will receive abiraterone and prednisone OR enzalutamide. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Treatment regimens evaluated in this trial are used in common mCRPC treatment practice and are reimbursed. Risk of side effects or death as a result of treatment is not affected by the trial design. At baseline, prior to each treatment cycle and at end of treatment, patients are requested to visit the out-patient clinic, where a physical exam will be performed in combination with vena puncture for blood analysis. Radiological evaluation will be performed at base line, after 3 months of treatment and at end of treatment. All above mentioned interventions can be considered as standard practice. Patients are requested to fill out QoL and pain/analgesic use questionnaires at base line, prior to each cycle and at end of treatment.
Status | Completed |
Enrollment | 100 |
Est. completion date | March 2, 2022 |
Est. primary completion date | December 16, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histological diagnosis of prostate adenocarcinoma. 2. Able and willing to provide informed consent and to comply with the study procedures 3. Age =18 4. Evidence of bone, visceral and/or lymph node metastases on bone scan, CT-scan or MRI. 5. Must have received at least one prior regimen of docetaxel treatment for at least 12 weeks (four courses) and no other prostate cancer treatments between docetaxel and randomization, other than prednisone. 6. Continued androgen deprivation therapy either by luteinizing hormone release hormone (LHRH) agonist/ antagonist or orchiectomy. 7. Treatment with curative intent is not an option and patient has an indication for systemic treatment as judged by the medical care provider 8. Evidence of progressive metastatic disease by PSA progression (Prostate Cancer Working Group 3 (PCWG3) criteria20: at least 2 rises at a minimum of 1-week intervals. The first PSA value must be = 2 ng/ml) and/or radiological progression as evaluated by chest, abdominal, or pelvic CT/MRI scan and/or bone scan within 28 days of registration (see Appendix III) 9. Poor prognosis disease as defined by any of the following: 1. The presence of liver metastases AND/OR 2. Development of castration-resistance within 12 months of orchiectomy or commencement of LHRH antagonist/agonist for metastatic disease AND/OR 3. Progressive disease during docetaxel treatment or <6 months after completion of docetaxel treatment 10. World Health Organization Performance Status (WHO PS) 0-2. 11. Serum testosterone < 50 ng/dL (< 1.7 nmol/L) within 28 days before treatment group allocation 12. At least 21 days have passed since completing radiotherapy (exception for a single fraction of = 800 centi-Gray (cGy) to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit: at least 7 days prior to randomization). 13. At least 21 days have passed since major surgery. 14. Neuropathy = grade 1 at the time of registration. 15. Has recovered from all therapy-related toxicity to = grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy) at the time of registration. 16. Eligible for cabazitaxel, abiraterone acetate or enzalutamide as per standard of care practices. 17. Men treated with cabazitaxel should use effective contraception throughout treatment and are recommended to continue this for up to 6 months after the last dose of cabazitaxel. Due to potential exposure via seminal liquid, men treated with cabazitaxel should prevent contact with the ejaculate by another person throughout treatment. Men being treated with cabazitaxel are advised to seek advice on conservation of sperm prior to treatment. Exclusion Criteria: 1. Histologic evidence of small cell/neuroendocrine prostate cancer 2. Any treatment other than prednisone between docetaxel and cabazitaxel/abiraterone OR enzalutamide sequence 3. Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus). 4. History of severe hypersensitivity reaction (= grade 3) to docetaxel, abiraterone or enzalutamide (whichever applies). 5. History of severe hypersensitivity reaction (= grade 3) to polysorbate 80 containing drugs. 6. Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments). 7. Patients who have a concurrent yellow fever vaccination (several weeks before start of treatment) must be excluded. 8. Dementia, altered mental status, or any psychiatric condition, if this is in conflict with the study. 9. Unable to swallow a whole tablet or capsule 10. Contraindications to the use of corticosteroid treatment 11. Symptomatic peripheral neuropathy Grade =2 (see Appendix VIII). 12. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured and needing no subsequent therapy. 13. Inadequate organ and bone marrow function as evidenced by: 1. Hemoglobin <10.0 g/dL 2. Absolute neutrophil count <1.5 x 109/L 3. Platelet count < 100 x 109/L 4. aspartate aminotransferase (AST)/ serum glutamate oxaloacetate transaminase (SGOT) and/ or Alanine Aminotransferase (ALT)/ serum glutamate pyruvate transaminase (SGPT) > 1.5 x (upper limit of normal) ULN Total bilirubin >1 x ULN (except for patients with documented Gilbert's disease). |
Country | Name | City | State |
---|---|---|---|
Netherlands | Noordwest Ziekenhuisgroep | Alkmaar | |
Netherlands | Bovenij ziekenhuis | Amsterdam | |
Netherlands | Rode Kruis Ziekenhuis | Beverwijk | |
Netherlands | Tergooi Ziekenhuizen | Blaricum | |
Netherlands | Deventer Ziekenhuis | Deventer | |
Netherlands | Slngeland Ziekenhuis | Doetinchem | |
Netherlands | Ziekenhuisgroep Twente | Hengelo | |
Netherlands | Spaarne Ziekenhuis | Hoofddorp | |
Netherlands | Dijklander ziekenhuis | Hoorn | |
Netherlands | Medisch Centrum leeuwarden | Leeuwarden | |
Netherlands | Academisch medisch centrum Maastricht | Maastricht | |
Netherlands | Sint Antonius ziekenhuis | Nieuwegein | |
Netherlands | Franciscus Gasthuis-Vlietland | Rotterdam | |
Netherlands | Zorgsaam Ziekenhuis | Terneuzen | |
Netherlands | Haga Ziekenhuis | The Hague | |
Netherlands | Diakonessenhuis | Utrecht | |
Netherlands | Universitair medisch centrum Utrecht | Utrecht | |
Netherlands | Viecuri medisch centrum Noord-Limburg | Venlo | |
Netherlands | Isala Klinieken | Zwolle |
Lead Sponsor | Collaborator |
---|---|
The Netherlands Cancer Institute |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory objectives; neutrophil to lymphocyte ratio | Prostate cancer is a very diverse disease and there is a need for more personalized treatment than offered nowadays. Therefore, three biomarker studies are included in this randomized trial. The value of the neutrophil to lymphocyte ratio will be measured in all patients, to try to find a predictive value | For each patient: until the end of treatment, Arm A max 30 weeks, Arm B max 24 months | |
Other | Exploratory objectives; number of mutations in 73 genes from cell-free DNA | We will draw blood from patients to measure mutations in 73 prostate cancer-related genes out of cell-free DNA. The goal again is to find a predictive value in these DNA mutations and to be able to give more personalized treatment. | For each patient: until the end of treatment, Arm A max 30 weeks, Arm B max 24 months | |
Other | Exploratory objectives; epigenetics-based biomarker discovery using cfDNA | We will isolate chromatinized cfDNA from serum samples of all patients in this trial. Immunoprecipitation will be performed for H3K27ac after which isolated DNA fragments are sequenced, effectively sequencing the enriched functional enhancers that are detected in the serum-derived cfDNA. The aim is to identify distinct functional enhancers that enable outcome prediction. | For each patient: until end of treatment (max 24 months) | |
Primary | Clinical benefit rate | • To assess the Clinical Benefit Rate (CBR) in patients with mCRPC and poor prognostic factors treated with cabazitaxel (Arm A) or novel hormonal agents (abiraterone OR enzalutamide) as second-line therapy (Arm B) who have been treated with docetaxel. | From start treatment until 12 weeks of treatment | |
Secondary | Comparing clinical benefit rate in arm A and arm B | • To formally compare the Clinical Benefit Rate (CBR) in both study arms A and B. | From start treatment until 12 weeks of treatment | |
Secondary | Duration of treatment | • To determine duration of treatment (DOT) in mCRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy and for those who cross over to the other study arm as a third-line therapy. | for each patient; until end of treatment (for Arm A max 30 weeks, for Arm B max 24 months) | |
Secondary | Progression free survival | • To determine the Progression Free Survival (PFS) of mCRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy and for those who cross over to the other study arm as a third-line therapy. | for each patient; until progression or through study completion (max 24 months) | |
Secondary | Overall survival | • To determine the Overall Survival (OS) of mCRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy. | for each patient; until death or end of trial (max 24 months) | |
Secondary | (serious) adverse events according to the ctcae v4.03: number of incidents, number of participants with (S)AE's | • To evaluate safety and toxicity profile of cabazitaxel and novel hormone agents (abiraterone OR enzalutamide) as a second line treatment. | for each patient: until 28 days after the last treatment | |
Secondary | Quality of Life assesed by the FACT-P questionnaire | • Quality of Life (QoL) as assessed by Fundamental Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire in metastatic CRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy. | for each patient; until start of the next therapy, death or end of trial (max 24 months) | |
Secondary | Quality of Life as assessed by the BPI-S questionnaire | • Quality of Life (QoL) as assessed Brief Pain Inventory-Short form (BPI-S) questionnaire in metastatic CRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy. | for each patient; until start of the next therapy, death or end of trial (max 24 months) | |
Secondary | Use of pain medication, assessed by a questionnaire about opiate use. | Use of pain medication, assessed by a questionnaire about opiate use in metastatic CRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy. | for each patient; until start of the next therapy, death or end of trial (max 24 months) | |
Secondary | Time to symptomatic progression | Time To Symptomatic Progression (TTSP) in CRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy and for those who cross over to the other study arm as a third-line therapy. | for each patient: until symptomatic progression or through study completion (max 24 months) | |
Secondary | Time to PSA progression | Time To PSA Progression (TTPP) in mCRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy and for those who cross over to the other study arm as a third-line therapy. | for each patient: until PSA progression or through study completion (max 24 months) | |
Secondary | Time to Radiological progression | Time To Radiological Progression (TTRP) in mCRPC patients treated with cabazitaxel or novel hormone agents (abiraterone OR enzalutamide) as second-line therapy and for those who cross over to the other study arm as a third-line therapy. | for each patient: until radiological progression or through study completion (max 24 months) | |
Secondary | PSA>50% decrease | Rate of PSA>50% decrease from baseline | for each patient; from baseline until end of trial (max 24 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01201096 -
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
|
N/A | |
Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01199822 -
Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Completed |
NCT00313859 -
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT05095207 -
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04392479 -
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
|
Phase 3 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Terminated |
NCT03652493 -
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05061082 -
Genomic Evolution of Metastasis in Gastric Cancer
|
||
Not yet recruiting |
NCT06055764 -
Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
|
||
Terminated |
NCT02796729 -
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
|
Phase 2 | |
Withdrawn |
NCT01157039 -
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
|
Phase 2 | |
Terminated |
NCT01000948 -
A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01613482 -
TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention
|
Phase 3 | |
Withdrawn |
NCT00244348 -
Hepatic Artery Infusion With Oxaliplatin
|
Phase 1/Phase 2 | |
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A |